Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $61,880 | 23 | 96.3% |
| Travel and Lodging | $2,228 | 6 | 3.5% |
| Education | $64.50 | 1 | 0.1% |
| Food and Beverage | $54.29 | 3 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $36,205 | 15 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $11,883 | 10 | $0 (2018) |
| Novocure GmbH | $6,720 | 2 | $0 (2022) |
| Novocure Inc. | $4,800 | 1 | $0 (2020) |
| EISAI INC. | $3,000 | 2 | $0 (2019) |
| VIVUS, Inc. | $1,000 | 1 | $0 (2017) |
| AstraZeneca UK Limited | $555.00 | 1 | $0 (2022) |
| GlaxoSmithKline, LLC. | $64.50 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,555 | 3 | Merck Sharp & Dohme LLC ($5,490) |
| 2023 | $10,930 | 4 | Merck Sharp & Dohme LLC ($10,930) |
| 2022 | $13,485 | 6 | Merck Sharp & Dohme LLC ($9,410) |
| 2021 | $6,200 | 2 | Novocure GmbH ($3,200) |
| 2020 | $10,550 | 3 | Merck Sharp & Dohme Corporation ($5,750) |
| 2019 | $3,125 | 3 | Merck Sharp & Dohme Corporation ($1,625) |
| 2018 | $13,383 | 11 | Takeda Pharmaceuticals U.S.A., Inc. ($11,883) |
| 2017 | $1,000 | 1 | VIVUS, Inc. ($1,000) |
All Payment Transactions
33 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/30/2024 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Consulting Fee | Cash or cash equivalent | $2,745.00 | General |
| Category: ONCOLOGY | ||||||
| 10/02/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,745.00 | General |
| Category: ONCOLOGY | ||||||
| 09/09/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Education | In-kind items and services | $64.50 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,135.00 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2023 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Consulting Fee | Cash or cash equivalent | $2,745.00 | General |
| Category: ONCOLOGY | ||||||
| 06/12/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $3,050.00 | General |
| Category: ONCOLOGY | ||||||
| 03/29/2023 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,440.00 | General |
| Category: ONCOLOGY | ||||||
| 08/03/2022 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: ONCOLOGY | ||||||
| 06/03/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,220.00 | General |
| Category: ONCOLOGY | ||||||
| 04/06/2022 | Novocure GmbH | — | Consulting Fee | Cash or cash equivalent | $3,520.00 | General |
| 01/19/2022 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,750.00 | General |
| Category: ONCOLOGY | ||||||
| 01/16/2022 | AstraZeneca UK Limited | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $555.00 | General |
| Category: Oncology | ||||||
| 07/16/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: ONCOLOGY | ||||||
| 04/13/2021 | Novocure GmbH | — | Consulting Fee | Cash or cash equivalent | $3,200.00 | General |
| 09/15/2020 | Novocure Inc. | Oncology (Device) | Consulting Fee | Cash or cash equivalent | $4,800.00 | General |
| Category: Optune | ||||||
| 08/12/2020 | Merck Sharp & Dohme Corporation | MK-7339 (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: ONCOLOGY | ||||||
| 01/27/2020 | Merck Sharp & Dohme Corporation | MK-7339 (Drug) | Consulting Fee | Cash or cash equivalent | $2,750.00 | General |
| Category: ONCOLOGY | ||||||
| 07/05/2019 | Merck Sharp & Dohme Corporation | MK-7339 (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ONCOLOGY | ||||||
| 07/05/2019 | Merck Sharp & Dohme Corporation | MK-7339 (Drug) | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| Category: ONCOLOGY | ||||||
| 06/26/2019 | EISAI INC. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 09/25/2018 | Eisai Inc. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 03/12/2018 | Takeda Pharmaceuticals U.S.A., Inc. | — | Travel and Lodging | Cash or cash equivalent | $117.50 | General |
| 03/09/2018 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $9,600.00 | General |
| 03/09/2018 | Takeda Pharmaceuticals U.S.A., Inc. | — | Travel and Lodging | In-kind items and services | $61.25 | General |
About Dr. Jonathan Berek, MD
Dr. Jonathan Berek, MD is a Obstetrics & Gynecology healthcare provider based in Stanford, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1164447900.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jonathan Berek, MD has received a total of $64,227 in payments from pharmaceutical and medical device companies, with $5,555 received in 2024. These payments were reported across 33 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($61,880).
Practice Information
- Specialty Obstetrics & Gynecology
- Other Specialties Gynecologic Oncology
- Location Stanford, CA
- Active Since 07/13/2006
- Last Updated 04/19/2024
- Taxonomy Code 207V00000X
- Entity Type Individual
- NPI Number 1164447900
Products in Payments
- KEYTRUDA (Biological) $11,590
- LYNPARZA (Biological) $8,490
- MK-7339 (Drug) $7,375
- Oncology (Device) $4,800
- QSYMIA (Drug) $1,000
- IMFINZI (Biological) $555.00
- ZEJULA (Drug) $64.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Obstetrics & Gynecology Doctors in Stanford
Amer Karam, Md, MD
Obstetrics & Gynecology — Payments: $207,508
Paul Blumenthal, Md, MD
Obstetrics & Gynecology — Payments: $22,302
Eric Sokol, Md, MD
Obstetrics & Gynecology — Payments: $12,802
Suji Uhm, Md, MD
Obstetrics & Gynecology — Payments: $8,399
Jing Wang Chiang, Md, MD
Obstetrics & Gynecology — Payments: $7,718
Amreen Husain, Md, MD
Obstetrics & Gynecology — Payments: $7,325